Transition Bio, Inc.
PrivateLast Round
Series A
Jun 2, 2022
Total Funding Raised
$50M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Transition Bio, Inc. operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in June 2022.
Transition Bio, Inc. is a biotechnology company that operates a drug discovery platform using biophysical sciences and artificial intelligence to map and modulate biomolecular condensates.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transition Bio, Inc. Comparables
Compare Transition Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nereid | 89% | |
| Dewpoint Therapeutics | 88% | |
| Nuage Therapeutics | 85% |
For institutional investors. Book with your work email.
Transition Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 2, 2022 | ||||
| Seed | Sep 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Transition Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Magnetic Ventures | Series A |
| Taiho Ventures | Series A |
| Lifeforce Capital | Series A, Seed |
| Northpond Ventures | Series A |
| Cambridge Enterprise | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 84% MoM, reaching 1.1K.
- Jun 22, 2026
Monthly visitors increased 45% MoM.
For institutional investors. Book with your work email.
Transition Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Transition Bio, Inc.'s valuation, stock price, and market status.
Is Transition Bio, Inc. a public or private company?
Transition Bio, Inc. is a private company.
What is the current stock price of Transition Bio, Inc.?
Transition Bio, Inc. is a private company, so its shares have no public market price. Caplight tracks Transition Bio, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Transition Bio, Inc. worth (valuation)?
Valuation information for Transition Bio, Inc. is not publicly available.
Can I buy Transition Bio, Inc. stock?
Transition Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Transition Bio, Inc.'s last funding round?
Transition Bio, Inc.'s most recent funding round was Series A on June 2, 2022.
Who are the main investors in Transition Bio, Inc.?
Key investors in Transition Bio, Inc. include Lifeforce Capital, Northpond Ventures.
Will Transition Bio, Inc. IPO soon?
No public IPO plans have been announced for Transition Bio, Inc..
How can I track Transition Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Transition Bio, Inc.'s shares on secondary markets.